Compare Stocks → The Gold Grab of the Century (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KRYS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$158.79+1.2%$164.33$82.09▼$189.97$4.53B0.85359,400 shs5,757 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech0.00%-1.04%-11.83%+31.73%+86.76%A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKRYSKrystal Biotech4.1184 of 5 stars2.51.00.04.72.63.31.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech3.00Buy$171.007.69% UpsideCurrent Analyst RatingsLatest KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$200.004/16/2024KRYSKrystal BiotechStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$178.00 ➝ $204.002/27/2024KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $175.002/27/2024KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$160.00 ➝ $195.002/27/2024KRYSKrystal BiotechWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 4/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$50.70M89.29N/AN/A$27.60 per share5.75Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$10.93M$0.081,985.1240.10N/AN/A-13.31%-12.61%5/6/2024 (Confirmed)Latest KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2024N/AKRYSKrystal Biotech$0.28N/A-$0.28N/AN/AN/A 2/26/202412/31/2023KRYSKrystal Biotech-$0.52$0.30+$0.82$0.30$27.43 million$42.14 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A17.7617.55OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech14.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech22928.51 million24.49 millionOptionableKRYS HeadlinesSourceHeadlineKrystal Biotech (KRYS) to Release Quarterly Earnings on Mondaymarketbeat.com - April 29 at 7:44 AMExeliom to focus on gastric cancer landscape with immune modulating drugclinicaltrialsarena.com - April 26 at 3:36 PMKrystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024globenewswire.com - April 26 at 7:00 AMKrystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of "Buy" by Analystsamericanbankingnews.com - April 26 at 3:24 AMBrookings takes closer look at Pitt BioForge, Krystal Biotech success in Pittsburghbizjournals.com - April 24 at 6:28 PMHandelsbanken Fonder AB Has $15.28 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)marketbeat.com - April 24 at 6:48 AMDown -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaroundzacks.com - April 23 at 10:36 AMJennison Associates LLC Buys 383,495 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)marketbeat.com - April 23 at 8:30 AMKrystal Biotech (NASDAQ:KRYS) Given "Buy" Rating at HC Wainwrightamericanbankingnews.com - April 23 at 3:34 AMKrystal Biotech (NASDAQ:KRYS) Receives Buy Rating from HC Wainwrightmarketbeat.com - April 22 at 2:24 PMKrystal Biotech moves to next step in clinical trialbizjournals.com - April 22 at 1:44 PMKrystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lungglobenewswire.com - April 22 at 7:00 AMKrystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Calamos Advisors LLCmarketbeat.com - April 22 at 6:14 AMCentury Real Estate raises ₹450 crore from Edelweiss to buy land and pay debtsmsn.com - April 18 at 7:23 AMAllspring Global Investments Holdings LLC Has $7.36 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)marketbeat.com - April 18 at 5:22 AMKrystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainablezacks.com - April 17 at 9:51 AM6,624 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Acquired by HealthInvest Partners ABmarketbeat.com - April 16 at 6:50 PMStifel Nicolaus Reaffirms "Buy" Rating for Krystal Biotech (NASDAQ:KRYS)marketbeat.com - April 16 at 8:46 AMRecent 3.8% pullback isn't enough to hurt long-term Krystal Biotech (NASDAQ:KRYS) shareholders, they're still up 437% over 5 yearsfinance.yahoo.com - April 15 at 11:29 AMKarnataka 2nd PUC Result 2024 DECLARED: How to check Class 12 result at karresults.nic.in, other official websitemsn.com - April 12 at 12:30 PMThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticalsfinance.yahoo.com - April 12 at 12:30 PMAnbio introduces cutting-edge “Point of Care” technology in Europeasiaone.com - April 8 at 1:36 PMBuy or sell: BHEL to Bajaj Finserv — Sumeet Bagadia recommends three stocks to buy on Monday — April 8livemint.com - April 8 at 1:36 PMKrystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meetingtmcnet.com - April 4 at 8:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsKrystal BiotechNASDAQ:KRYSKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
